Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Lineage Cell Therapeutics Inc’s stock clocked out at $0.94, down -3.02% from its previous closing price of $0.96. In other words, the price has decreased by -$3.02 from its previous closing price. On the day, 23.64 million shares were traded. LCTX stock price reached its highest trading level at $1.09 during the session, while it also had its lowest trading level at $0.9117.
Ratios:
To gain a deeper understanding of LCTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.82 and its Current Ratio is at 3.82. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on August 20, 2024, initiated with a Buy rating and assigned the stock a target price of $4.
On November 02, 2022, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $5.
On June 14, 2022, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.B. Riley Securities initiated its Buy rating on June 14, 2022, with a $4 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 27 ’25 when BROADWOOD PARTNERS, L.P. bought 7,894,737 shares for $0.76 per share. The transaction valued at 6,000,000 led to the insider holds 49,560,992 shares of the business.
Howe Jill Ann bought 15,000 shares of LCTX for $8,850 on Nov 26 ’24. The Chief Financial Officer now owns 25,500 shares after completing the transaction at $0.59 per share. On Nov 26 ’24, another insider, Samuel George A. III, who serves as the General Counsel of the company, bought 15,000 shares for $0.60 each. As a result, the insider paid 9,000 and bolstered with 22,184 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LCTX now has a Market Capitalization of 213558528 and an Enterprise Value of 166524800. For the stock, the TTM Price-to-Sale (P/S) ratio is 22.34 while its Price-to-Book (P/B) ratio in mrq is 2.70. Its current Enterprise Value per Revenue stands at 17.424 whereas that against EBITDA is -8.035.
Stock Price History:
The Beta on a monthly basis for LCTX is 1.61, which has changed by -0.0105262995 over the last 52 weeks, in comparison to a change of 0.12748289 over the same period for the S&P500. Over the past 52 weeks, LCTX has reached a high of $1.15, while it has fallen to a 52-week low of $0.37. The 50-Day Moving Average of the stock is 49.77%, while the 200-Day Moving Average is calculated to be 42.12%.
Shares Statistics:
It appears that LCTX traded 1.72M shares on average per day over the past three months and 6254260 shares per day over the past ten days. A total of 228.36M shares are outstanding, with a floating share count of 227.36M. Insiders hold about 0.44% of the company’s shares, while institutions hold 48.65% stake in the company. Shares short for LCTX as of 1749772800 were 28728210 with a Short Ratio of 16.72, compared to 1747267200 on 29963709. Therefore, it implies a Short% of Shares Outstanding of 28728210 and a Short% of Float of 22.45.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
